Home Depot Inc vs Novo Nordisk A/S — how do they compare? Home Depot Inc trades at $345.3 (market cap $353.46B), while Novo Nordisk A/S trades at $46.23 (market cap $207.85B). The key difference: Home Depot Inc is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| HD | NVO | |
|---|---|---|
Market Cap | $353.46B | $207.85B |
Sector | Consumer Cyclical | Health |
52-Week High | $423.42 | $63.98 |
52-Week Low | $297.51 | $35.29 |
Enterprise Value | $415.01B | $222.55B |
Dividend Yield | 2.63% | 3.81% |
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $344.63, down 1.75% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. Recent earnings show mixed quarterly beats, with Q2 2026 results pending. Revenue grew to $159.51 billion in 2025, though net margins have declined to 8.41%. The stock benefits from strong analyst support, with a consensus price target of $371.25, and a dividend payment scheduled for June 2026.
The stock presents a long-term opportunity driven by Pro customer growth and housing tailwinds, but faces risks from weakening big-ticket demand and margin pressures. With 59% of analysts rating it a buy, upside exists if earnings rebound, though high valuation multiples and economic sensitivity warrant caution.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Trailing returns across standard periods
Latest headlines on both assets
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →